Oral Antacid-Formulated PDE10A Inhibitor Therapy for Targeting RAS-Driven Cancers and Immune Modulation

ADT-030 is an oral cancer drug, formulated with an antacid for safety, that targets KRAS-driven tumors by blocking key cancer pathways and boosting immune response, showing strong effectiveness even against cancers resistant to other treatments.

Background

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal forms of cancer, with a five-year survival rate of less than 13%. This dire prognosis is largely due to the aggressive nature of the disease, its complex tumor microenvironment, and its ability to evade the immune system. A defining characteristic of PDAC is the high prevalence of KRAS mutations, which are present in approximately 90% of cases and drive continuous activation of key growth and survival pathways. Additionally, aberrant Wnt/β-catenin signaling further contributes to tumor progression and resistance to conventional therapies. The interplay between these pathways creates a formidable barrier to effective treatment, underscoring the urgent need for new therapeutic strategies that can address the multifaceted biology of PDAC and other RAS-driven cancers.

Current treatment options, including recently developed allele-specific KRAS inhibitors, have shown some promise but are limited in scope and effectiveness. These inhibitors typically target only specific KRAS mutations, leaving the majority of patients without viable options. Moreover, even in cases where these drugs are initially effective, resistance frequently develops, rendering the treatments ineffective over time. Other approaches, such as targeting downstream signaling pathways or combining therapies, have been hampered by toxicity, lack of selectivity, and limited ability to modulate the tumor immune microenvironment. Furthermore, many promising compounds suffer from poor oral bioavailability and formulation challenges, which restrict their clinical utility. Collectively, these limitations highlight the need for novel agents that can simultaneously target multiple oncogenic pathways, overcome resistance mechanisms, and be delivered safely and effectively to patients.

Technology

ADT-030 is an orally administered phosphodiesterase 10A (PDE10A) inhibitor specifically designed for the treatment of RAS-driven cancers, including pancreatic ductal adenocarcinoma (PDAC) and other malignancies characterized by KRAS mutations. Structurally related to sulindac but optimized for selective PDE10A inhibition, ADT-030 elevates intracellular cyclic nucleotides (cGMP and cAMP), thereby activating protein kinases that disrupt multiple cancer-promoting pathways. The compound indirectly inhibits both RAS and β-catenin signaling, resulting in cancer cell apoptosis, cell cycle arrest, and autophagy modulation. A critical aspect of its formulation is the inclusion of an antacid, which significantly enhances oral bioavailability and mitigates toxicity, overcoming limitations seen with earlier water-based formulations. Preclinical studies demonstrate robust antitumor activity, including suppression of tumor growth, reduction of metastasis, and durable responses in both cell line-derived and patient-derived xenograft models.

What differentiates this technology is its dual-action mechanism and innovative formulation strategy. Unlike current allele-specific KRAS inhibitors, which are limited by mutation specificity and resistance development, ADT-030 targets broader oncogenic networks by simultaneously disrupting RAS and β-catenin pathways, effectively overcoming resistance in cancer cells that no longer respond to existing targeted therapies. Additionally, ADT-030 uniquely remodels the tumor immune microenvironment, increasing infiltration and activation of both adaptive and innate immune cells while shifting macrophage populations toward a pro-inflammatory, tumor-fighting phenotype. The antacid-based formulation not only addresses solubility and metabolic challenges but also enables safe and effective oral delivery, eliminating the need for prodrug modifications. This combination of broad-spectrum molecular targeting, immune modulation, and formulation innovation positions ADT-030 as a highly promising candidate for the treatment of some of the most difficult-to-treat cancers.

Benefits

  • Selective inhibition of KRAS mutant cancer cells, sparing wild-type cells
  • Dual mechanism targeting RAS and β-catenin signaling pathways to induce apoptosis, cell cycle arrest, and autophagy modulation
  • Effective oral delivery enabled by antacid formulation improving bioavailability and reducing toxicity
  • Robust antitumor efficacy demonstrated in multiple preclinical models, including tumor regression and metastasis prevention
  • Immune microenvironment remodeling with increased adaptive and innate immune cell activation and reduced immunosuppression
  • Ability to overcome resistance to allele-specific KRAS inhibitors
  • Potential for combination therapy with chemotherapy or immunotherapy to enhance clinical outcomes

Applications

  • KRAS-mutant pancreatic cancer therapy
  • Resistant KRAS-driven cancer treatment
  • Combination therapy with immunotherapy
  • Oral anticancer drug formulation

Additional info

ADT-030 is an indenyl derivative and phosphodiesterase 10A inhibitor, orally delivered with an antacid. It elevates cGMP, activating PKG to inhibit RAS and beta-catenin pathways, inducing cancer cell apoptosis, cell cycle arrest, and immune modulation. This compound targets RAS-driven malignancies, overcoming resistance, with the antacid enhancing bioavailability and safety.